Back to Search Start Over

U.S. FDA Approves Mylan and Biocon's Fulphila (pegfilgrastim-jmdb), the First Biosimilar to Neulasta(r)

Source :
Plus Company Updates. June 5, 2018
Publication Year :
2018

Abstract

Netherlands: MYLAN N.V. has issued the following press release: Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
Plus Company Updates
Publication Type :
News
Accession number :
edsgcl.542892502